Responding cells included pre-treatment PBMC (negative control) and post-treatment PBMC that were suspended in complete medium and AIM-V (1:1 ratio) with OKT3 (30ng/ml) and IL-2 (300IU/ml). serum revealed that antibody binding was beta chain specific in one patient whereas it was alpha chain specific in another. == Conclusions == A subset of patients treated with mTCR engineered T-cells developed antibodies directed to the mTCR variable regions and not to the constant region domains common to all mTCR. Overall, the development of a host immune response was not associated with the level of transduced cell persistence or response to therapy. In summary, patients treated with mTCR can develop an immune response to gene-modified cells in a minority of cases, but this may not affect clinical outcome. Keywords:Immunity, gene therapy, T-cell receptor == Statement of Translational Relevance == Human gene therapy has application not only in oncology, but also in the treatment of a variety of conditions as diverse as cardiovascular disease and HIV infection. The development of immunity to gene transfer components can be an obstacle to successful gene therapy. Our report describes a subset of patients enrolled in cancer gene therapy trials that developed an immune response to lymphocytes expressing Proteasome-IN-1 murine T-cell receptors (mTCR). These responses were observed in both responding and non-responding patients suggesting that the development of immunity to mTCR does not preclude effective treatment. Because HLA-A2 transgenic mice can be used to derive mTCR against common tumor antigens such as p53 and CEA, the Proteasome-IN-1 potential application of mTCR-based cell therapies has board implications for the treatment of a variety of malignancies. == Introduction Proteasome-IN-1 == Gene therapy has evolved significantly since Spry1 the first report two decades ago, which demonstrated the safety and feasibility of human gene transfer (1). At the end of 2009, cancer research accounted for almost 70% of human gene transfer protocols that had been reviewed by the Recombinant DNA Advisory Committee, NIH (2). Our efforts have involved the genetic modification of human lymphocytes used in adoptive cell transfer (ACT) for the treatment of patients with metastatic melanoma. In a series of clinical trials involving 93 patients with metastatic melanoma treated with autologous tumor infiltrating lymphocytes (TIL) following a lymphodepleting regimen, an objective cancer regression rate of 56% was seen. Some patients experienced a clonal repopulation of T cells specific for the melanoma/melanocyte differentiation antigen, MART-1, which suggested that this self-antigen could be a useful target for cancer immunotherapy (3). To bypass the need to obtain lymphocytes from a tumor specimen, a method was developed to transduce peripheral blood lymphocytes (PBL) with a retrovirus encoding a T cell receptor (TCR) that could recognize the MART-1 tumor-associated antigen. The TCR alpha and beta chains of a MART-1-reactive TIL clone were identified in a patient who demonstrated near complete regression of metastatic melanoma after adoptive cell transfer of TIL (3,4). Autologous PBL were transduced ex vivo with anti-MART-1 TCR genes and reinfused into 15 patients with widely metastatic melanoma. Although the response rate was 13% (2 of 15), less than that achieved with autologous TIL, the method proved that PBL engineered to express TCRs recognizing tumor-associated antigens could mediate the regression of large solid tumors in humans (4). Extensive screening of human T-cell clones that recognized the MART-12735epitope identified a second more highly reactive human TCR for use in ACT (5,6). In parallel work highly avid murine lymphocytes against gp100154162and p53264272epitopes were identified by immunization of human leukocyte antigen-A2 (HLA-A2) transgenic mice, and the genes encoding murine TCRs (mTCR) from those cells were used to transduce human lymphocytes as well (5,710). In recent clinical trials these new high-avidity anti-gp100 and anti-MART-1 TCRs were used to treat patients with metastatic melanoma (6). Following a lymphodepleting chemotherapy regimen, 36 patients received autologous peripheral blood lymphocytes transduced with these TCRs (16 with murine anti-gp100 and 20 patients with human anti-MART-1). Objective tumor regression was seen in 19% and 30% of patients receiving the gp100- and MART-1-specific TCRs, respectively. In a third clinical trial,.